Expression of a dominant T cell receptor can reduce toxicity and enhance tumor protection of allogeneic T cell therapy

Angelika Holler, Mathias Zech, Sara Ghorashian, Rebecca Pike, Alastair Hotblack, Pedro Veliça, Shao-An Xue, Ronjon Chakraverty, Emma C. Morris, and Hans J. Stauss

Disclosures: H.J.S. is a scientific advisor and share holder at Cell Medica. The remaining authors declare no competing financial interests. This work was supported by Leukaemia & Lymphoma Research UK, Medical Research Council, EU ATTRACT consortium, CRUK Experimental Cancer Medicine Centre, NIHR UCL/UCLH Biomedical Research Centre and NIHR CRN

Contributions: HJS and AH designed experiments, AH, MZ, SG, RP, AH, PV and SX performed experiments, AH, RC, ECM and HJS analysed data, AH and HJS wrote paper.